Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

P51449 (RORG_HUMAN) Homo sapiens (Human)

Nuclear receptor ROR-gamma UniProtKBInterProSTRINGInteractive Modelling

518 aa; Sequence (Fasta) ; (Isoform 2); 1 identical sequence: Homo sapiens: Q6I9R9

Available Structures

156 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Crystal structure of orphan nuclear receptor RORgamma in complex with natural ligand Heteromer
Q15596;
261-507
HC3;
Assess
ROR gamma in complex with SCR2 and compound 3 Heteromer
Q15596;
262-507
WB7;GOL;
Assess
Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for … Heteromer
P48552;
264-508
98N;
Assess
RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST "CPD-9" AND RIP140 PEPTIDE AT 1.66A Heteromer
P48552;
264-508
EEZ;
Assess
RORGT (264-518;C455S) IN COMPLEX WITH THE FRAGMENT ("CPD-1") AND RIP140 PEPTIDE AT 1.80A Heteromer
P48552;
264-508
EE8;
Assess
Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for … Heteromer
P48552;
264-508
8YB;
Assess
RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST "CPD-2" AND RIP140 PEPTIDE AT 1.90A Heteromer
P48552;
264-508
EF5;
Assess
Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for … Heteromer
P48552;
264-508
98H;
Assess
Crystal structure of the orphan nuclear receptor ROR(gamma)t ligand-binding domain in complex with … Heteromer
Q15596;
264-508
NBH;DMX;
Assess
Structure of RORgt in complex with a novel agonist. Heteromer
Q15788;
263-507
EDO;HOJ;
Assess
Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for … Heteromer
P48552;
264-508
C3S;
Assess
Crystal structure of the orphan nuclear receptor RORgamma ligand-binding domain in complex with 4al… Heteromer
P48552;
263-507
4D8;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
VYI;DMS;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
JUH;NA;DMS;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
VCH;DMS;NA;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
4TU;NA;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
6VD;NA;
Assess
Crystal structure of RORgamma in complex with natural inverse agonist Heteromer
Q15596;
265-507
88K;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
8Y5;NA;DMS;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
JUN;DMS;NA;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
BWE;NA;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
I6G;SWX;YTZ;NA;DMS;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
8Y2;NA;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
VCK;NA;DMS;
Assess
Crystal structure of RORgamma in complex with natural inverse agonist Heteromer
Q15596;
265-507
97I;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
A7W;NA;DMS;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
76E;NA;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
JUE;NA;
Assess
RORgamma (263-509) complexed with SRC2 and Compound 6 Heteromer
Q15788;
265-507
4CX;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
8YB;NA;
Assess
Crystal structure of orphan nuclear receptor RORgamma in complex with natural ligand Heteromer
Q15596;
265-507
HC2;
Assess
Crystal structure of orphan nuclear receptor RORgamma in complex with natural ligand Heteromer
Q15596;
265-507
HC9;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
8Y8;NA;DMS;
Assess
Ligand complex of RORg LBD Heteromer
Q15596;
265-507
5IM;
Assess
Crystal structure of RORgamma complexed with SRC2 and compound 5d Heteromer
Q15596;
265-507
4CZ;
Assess
Ligand complex of RORg LBD Heteromer
265-500
76E;
Assess
Complex of a Gemini-cholesterol analogue with Retinoid-related Orphan Receptor gamma Heteromer
264-497
ACT;ECK;
Assess
Ternary complex of Human ROR gamma Ligand Binding Domain With Compound T. Heteromer
Q9Y618;
263-493
9P6;
Assess
Crystal Structure of the mutant Human ROR gamma Ligand Binding Domain With rockogenin. Heteromer
Q9Y618;
266-493
82R;
Assess
Discovery of the Second Generation ROR gamma Inhibitors Composed of an Azole Scaffold. Heteromer
Q9Y618;
266-492
AYO;
Assess
Crystal structure of RORc in complex with a partial inverse agonist compoundhomo-2-mer262-507
3QQ;TLA;
Assess
Structure of RORgt bound to a tertiary alcoholhomo-2-mer265-481
9WD;
Assess
Structure of RORgt bound to a tertiary alcoholhomo-2-mer267-475
9WA;
Assess
Crystal Structure of human RORgamma (C455E) LBD in complex with compound XY039homo-2-mer266-466
H4I;GOL;EOH;
Assess
HUMAN RETENOID-RELATED ORPHAN RECEPTOR-GAMMA (RORC2) LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND…monomer259-507
XO5;XNX;
Assess
HUMAN RETENOID-RELATED ORPHAN RECEPTOR-GAMMA (RORC2) LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND…monomer260-507
LKY;4Y5;SO4;
Assess
HUMAN RETENOID-RELATED ORPHAN RECEPTOR-GAMMA (RORC2) LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND…monomer260-507
XNR;4Y5;
Assess
Crystal structure of RORc in complex with a phenyl sulfonamide agonistmonomer264-509
3SN;
Assess
RORgammat LBD complexed with Ursonic Acid and SRC2.2monomer265-509
B8F;
Assess
RORy in complex with T090131718 and Coactivator peptide EBI96monomer263-507
444;
Assess
SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTSmonomer265-508
Z7D;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE…monomer265-508
Z7G;
Assess
Crystal structure of RORgt with compound (4R)-6-[(2,5-dichloro-3-{[(2R,4R)-1-(cyclopentanecarbonyl)…monomer265-508
VK4;GOL;SO4;
Assess
SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTSmonomer265-508
TKJ;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244- 487)-L6-SRC1(678-692)) IN COMPL…monomer265-508
R7V;GOL;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692) IN COMPLEX…monomer265-508
YDY;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE…monomer265-508
Z7I;
Assess
SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTSmonomer265-508
Z7F;
Assess
Crystal structure of RORgt with 3-cyano-N-(3-{[(3S)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl…monomer265-508
LKY;EDO;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE…monomer265-508
Z7H;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(6T78-692) IN COMPLE…monomer265-508
VK7;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS- RORGT(244-487)-L6-SRC1(678-692)) IN COMPL…monomer265-508
O5B;GOL;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692) IN COMPLEX…monomer265-508
Z8G;
Assess
Crystal structure of RAR-related orphan receptor C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) in comple…monomer265-508
O5A;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE…monomer265-508
Z8I;
Assess
Crystal structure of RORgammat with ligand C46D boundmonomer265-507
ENU;
Assess
X-ray structure of nuclear receptor ROR-gammat Ligand Binding Domain + SRC2 peptidemonomer265-507
NA;
Assess
X-ray co-structure of nuclear receptor ROR-GAMMAT + SRC2 peptide with a benzothiadiazole dioxide in…monomer265-507
NA;GOL;ZBD;
Assess
X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with an inverse agonist and…monomer265-507
NA;927;
Assess
Crystal structure of RORgammat with ligand C46D boundmonomer265-507
EKL;
Assess
X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with an inverse agonist and…monomer265-507
NA;92A;
Assess
RORgamma (263-509) complexed with GSK2435341A and SRC2monomer265-507
43V;SO4;
Assess
Crystal structure of the ROR(gamma)t ligand binding domain in complex with 4-(1-(2-chloro-6-(triflu…monomer265-507
4F1;MG;
Assess
X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with an agonist and SRC2 pe…monomer265-507
NA;921;
Assess
Crystal structure of RORgammat with ligand C46D boundmonomer265-507
EO0;
Assess
RORgamma Ligand Binding Domainmonomer265-507
L77;
Assess
Complex structure of RORgama with betulinic acidmonomer265-507
06L;
Assess
Crystal structure of RORgammat with ligand C46D boundmonomer265-507
ENR;
Assess
RORgamma in complex with agonist BIO592 and Coactivator EBI96monomer265-507
6F1;CL;
Assess
X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with a inverse agonist and …monomer265-507
NA;9GS;
Assess
RORgamma LBD complexed with Panaxatriol and SRC2.2monomer265-507
HVL;
Assess
X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with a inverse agonist and …monomer265-507
9GV;
Assess
RORgamma Ligand Binding Domainmonomer265-507
L7J;
Assess
ROR(gamma)t ligand binding domain in complex with allosteric ligand FM216monomer266-507
UKB;
Assess
ROR(gamma)t ligand binding domain in complex with allosteric ligand FM26monomer266-507
L3E;
Assess
ROR(gamma)t ligand binding domain in complex with allosteric ligand FM257monomer266-507
UK8;
Assess
ROR(gamma)t ligand binding domain in complex with allosteric ligand FM217monomer266-507
U95;
Assess
Discovery of phenoxyindazoles and phenylthioindazoles as RORg inverse agonistsmonomer265-506
79U;
Assess
ROR(gamma)t ligand binding domain in complex with 25-hydroxycholesterol and allosteric ligand FM26monomer267-507
HC3;L3E;GOL;
Assess
ROR(gamma)t ligand binding domain in complex with 20-alpha-hydroxycholesterol and allosteric ligand…monomer267-507
GOL;L3E;HCD;
Assess
Identification of a Novel Allosteric Binding Site for RORgt Inhibitorsmonomer267-507
4Y6;SO4;GOL;
Assess
ROR(gamma)t ligand binding domain in complex with desmosterol and allosteric ligand FM26monomer267-507
MHQ;L3E;GOL;
Assess
ROR(gamma)t ligand binding domain in complex with cholesterol and allosteric ligand MRL871monomer267-507
CLR;4F1;GOL;
Assess
ROR(gamma)t ligand binding domain in complex with 25-hydroxycholesterol and allosteric ligand Glenm…monomer267-507
HC3;MJE;GOL;
Assess
ROR(gamma)t ligand binding domain in complex with desmosterol and allosteric ligand MRL871monomer267-507
MHQ;4F1;GOL;
Assess
ROR(gamma)t ligand binding domain in complex with cholesterol and allosteric ligand FM26monomer267-507
CLR;L3E;GOL;
Assess
ROR(gamma)t ligand binding domain in complex with 25-hydroxycholesterol and allosteric ligand MRL871monomer267-507
HC3;4F1;GOL;
Assess
Identification of a Novel Allosteric Binding Site for RORgt Inhibitorsmonomer267-507
4Y7;GOL;
Assess
Identification of a Novel Allosteric Binding Site for RORgt Inhibitorsmonomer267-507
4Y5;GOL;
Assess
Identification of a Novel Allosteric Binding Site for RORgt Inhibitorsmonomer267-507
4F1;GOL;SO4;
Assess
ROR(gamma)t ligand binding domain in complex with allosteric ligand compound 13 (Glenmark)monomer267-507
MJE;
Assess
Retinoic acid receptor-related orphan receptor (ROR) gamma in complex with allosteric compound 28monomer267-507
Q3Y;
Assess
ROR(gamma)t ligand binding domain in complex with allosteric ligand FM156monomer268-507
ULT;GOL;
Assess
ROR(gamma)t ligand binding domain in complex with 20-alpha-hydroxycholesterol and allosteric ligand…monomer268-507
GOL;MJE;HCD;
Assess
ROR(gamma)t ligand binding domain in complex with cholesterol and allosteric ligand Glenmarkmonomer268-507
CLR;MJE;GOL;
Assess
ROR(gamma)t ligand binding domain in complex with 20-alpha-hydroxycholesterol and allosteric ligand…monomer268-507
GOL;HCD;4F1;
Assess
ROR(gamma)t ligand binding domain in complex with desmosterol and allosteric ligand Glenmarkmonomer268-507
MJE;MHQ;GOL;
Assess
The Crystal Structure of RORgT from Biortus.monomer265-499
Assess
Crystal structure of RORc in complex with a benzyl sulfonamide inverse agonistmonomer265-498
3SX;SO4;
Assess
Crystal structure of RORc in complex with a tertiary sulfonamide inverse agonistmonomer265-498
39K;DMS;
Assess
Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for …monomer265-498
444;
Assess
RORgamma Ligand Binding Domainmonomer265-497
L7P;
Assess
HUMAN RETENOID-RELATED ORPHAN RECEPTOR-GAMMA LIGAND- BINDING DOMAIN IN COMPLEX WITH INDOLE LIGAND C…monomer265-495
F7M;
Assess
Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for …monomer263-492
98E;
Assess
RORC2 LBD complexed with compound 34monomer265-494
F7J;
Assess
Ligand complex of RORgt LBDmonomer265-494
9A0;EDO;DMF;
Assess
Ligand complex of RORg LBDmonomer265-493
D9N;
Assess
RORCVAR2 (RORGT, 264-499) IN COMPLEX WITH COMPOUND 4 AT 2.2A: Identification of N-aryl imidazoles a…monomer265-492
HKZ;
Assess
IDENTIFICATION OF BICYCLIC HEXAFLUOROISOPROPYL ALCOHOL SULFONAMIDES AS RORGT/RORC INVERSE AGONISTSmonomer265-492
XGH;SO4;
Assess
Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding doma…monomer265-492
6Q6;
Assess
Structure of RORgt in complex with a novel inverse agonist 2monomer265-492
CFJ;
Assess
Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORgtmonomer265-492
RG7;
Assess
Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding doma…monomer265-491
Assess
Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding doma…monomer265-491
6QW;
Assess
RORCVAR2 (RORGT, 264-499) IN COMPLEX WITH COMPOUND 2 AT 2.3A: Identification of N-aryl imidazoles a…monomer265-490
HKE;CHD;
Assess
RORCVAR2 (RORGT, 264-499) IN COMPLEX WITH COMPOUND 1: Identification of N-aryl imidazoles as potent…monomer265-490
HJW;
Assess
Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding doma…monomer265-490
6QP;
Assess
Synthesis and biological evaluation of new triazolo and imidazolopyridine RORgt inverse agonistsmonomer265-489
Q6Y;
Assess
Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for …monomer265-489
99N;
Assess
RORCVAR2 (RORGT, 264-499) IN COMPLEX WITH COMPOUND 9 AT 2.3A: Identification of N-aryl imidazoles a…monomer267-491
HL8;
Assess
Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding doma…monomer265-489
444;
Assess
Structure of RORgt bound tomonomer265-489
87J;
Assess
Identification and biological evaluation of thiazole-based inverse agonists of RORgtmonomer265-489
FJG;
Assess
Structure of RORgt bound tomonomer265-487
88J;
Assess
RORgamma in complex with inverse agonist 4j.monomer265-487
4Q3;
Assess
Crystal structure of RAR-related orphan receptor C in complex with a phenyl (3-phenylpyrrolidin-3-y…monomer265-487
L8A;
Assess
Structure of RORgt bound tomonomer265-487
8A4;
Assess
Crystal Structure Analysis of the ROR gamma(C455E)monomer266-487
B6L;
Assess
Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding doma…monomer265-486
6Q5;
Assess
Crystal structure of human ROR gamma LBD in complex with a quinoline sulfonamide inverse agonistmonomer267-487
HBW;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C IN COMPLEX WITH A NOVEL INVERSE AGONISTmonomer265-485
V27;
Assess
Crystal structure of the ligand binding domain of RORC with T0901317monomer266-486
444;
Assess
Identification and biological evaluation of tertiary ALCOHOL-based inverse agonists of RORgtmonomer265-485
KHY;
Assess
Crystal structure of human ROR gamma LBD in complex with a (quinolinoxymethyl)benzamide inverse ago…monomer269-487
LK8;
Assess
RORgamma in complex with inverse agonist BIO399.monomer269-487
6EW;
Assess
RORgamma in complex with inverse agonist 16monomer268-486
4P1;
Assess
Structure of RORgt in complex with a novel inverse agonist 3monomer265-482
CF7;
Assess
RORy in complex with inverse agonist 3.monomer269-486
5RT;
Assess
Structure of RORgt in complex with a novel inverse agonist.monomer265-481
SO4;MPD;HQ7;
Assess
Crystal Structure of the Human ROR gamma Ligand Binding Domain With 3gmonomer264-480
4LQ;
Assess
RORgamma in complex with inverse agonist 48monomer265-481
4P3;
Assess
Structure of RORgt in complex with a novel inverse agonist TAK-828.monomer265-480
MPD;E3V;
Assess
Crystal structure of the orphan nuclear receptor ROR(gamma)t ligand-binding domain in complex with …monomer265-479
DGX;
Assess
Structure of RORgt in complex with a novel inverse agonist 1monomer265-479
CFG;
Assess
Structure of RORgt in complex with a novel isoquinoline inverse agonist.monomer265-479
MPD;E3S;
Assess
CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C IN COMPLEX WITH A POTENT, SELECTIVE AND ORALLY B…monomer265-477
VBG;SO4;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
3dzy.1.Bmonomer0.5028-508
ZN;31.30
Assess

1 SWISS-MODEL model built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 23dzu.1.Bmonomer0.507-487
ZN;31.20
Assess